Cerebrovascular Disease is an indication for drug development with over 400 pipeline drugs currently active. According to GlobalData, preregistered drugs for Cerebrovascular Disease have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Cerebrovascular Disease compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cerebrovascular Disease overview
Cerebrovascular disease refers to a group of conditions that affect blood vessels supplying the brain, often leading to damage or dysfunction of brain tissue. The most common types of cerebrovascular disease include ischemic stroke, hemorrhagic stroke, and transient ischemic attack (TIA). Symptoms include sudden numbness or weakness in the face, arm, or leg, difficulty speaking or understanding speech, sudden severe headache, and loss of coordination. Diagnosis includes a combination of medical history, physical examination, imaging studies (such as CT or MRI scans), and laboratory tests
For a complete picture of PTSR and LoA scores for drugs in Cerebrovascular Disease, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
